Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells.

abstract：:Non-small cell lung cancer (NSCLC) is the world's leading cause of cancer death and about 75% of all patients have advanced disease incurable with localized treatments (surgery and radiotherapy) alone. The aims of therapy in these are palliation of symptoms and extension of life. A substantial body of evidence has eme...

journal_title：Anti-cancer drugs

authors： Nicum S,Cullen MH

更新日期：2000-09-01 00:00:00

abstract：:1,4-Anthraquinone (AQ) was synthesized and shown to prevent L1210 leukemic cells from synthesizing macromolecules and growing in vitro. In contrast, its dihydroxy-9,10anthraquinone precursor, quinizarin, was inactive. The antitumor activity of AQ was compared to that of daunorubicin (DAU), which is structurally differ...

journal_title：Anti-cancer drugs

authors： Perchellet EM,Magill MJ,Huang X,Dalke DM,Hua DH,Perchellet JP

更新日期：2000-06-01 00:00:00

abstract：:Extrachromosomal DNA is the predominant form of gene amplification in human tumors. Hydroxyurea (HU) concentrations of 100-150 microM have been promising in vitro for extrachromosomal DNA elimination. The study objective was to determine the HU dose-concentration relationship in nude mice with HU doses from 0 to 200 m...

journal_title：Anti-cancer drugs

authors： Van den Berg CL,McGill JR,Kuhn JG,Walsh JT,De La Cruz PS,Davidson KK,Wahl GM,Von Hoff DD

更新日期：1994-10-01 00:00:00

abstract：:The prognosis of children with high-grade glioma or high-risk neuroblastoma remains poor. Cilengitide is a selective antagonist of αvβ3 and αvβ5 integrins, which are involved in tumor growth and development of metastasis. We have evaluated the effects of cilengitide on pediatric glioma and neuroblastoma cell lines for...

journal_title：Anti-cancer drugs

authors： Leblond P,Dewitte A,Le Tinier F,Bal-Mahieu C,Baroncini M,Sarrazin T,Lartigau E,Lansiaux A,Meignan S

更新日期：2013-09-01 00:00:00

abstract：:The sea, covering 70% of the Earth's surface, offers a considerably broader spectrum of biological diversity than terra firma. Containing approximately 75% of all living organisms, the marine environment offers a rich source of natural products with potential therapeutic application. Marine organisms have evolved the ...

journal_title：Anti-cancer drugs

authors： Jimeno JM

更新日期：2002-05-01 00:00:00

abstract：:Twelve patients received intrapleural instilments of the cytostatic agent mitoxantrone in a total dosage of 30 mg for locoregional palliative therapy of malignant pleural effusion. Effusion could be stopped for a mean period of 3.2 months in 11 patients. ...

journal_title：Anti-cancer drugs

authors： Torsten U,Opri F,Weitzel H

更新日期：1992-02-01 00:00:00

abstract：:High expression of vascular endothelial growth factor (VEGF) in patients with breast cancer has been associated with a poor prognosis, indicating that VEGF could be linked to the efficacy of chemotherapy and radiotherapy. It has also been suggested that radiation resistance is partly due to tumour cell production of a...

journal_title：Anti-cancer drugs

authors： Heravi M,Tomic N,Liang L,Devic S,Holmes J,Deblois F,Radzioch D,Muanza T

更新日期：2012-06-01 00:00:00

abstract：:Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to determine if corticosteroid co-medication reduces the incidence and severity of docetaxel-induced neuropathy. Two groups of patients treated with docetaxel in ...

journal_title：Anti-cancer drugs

authors： Pronk LC,Hilkens PH,van den Bent MJ,van Putten WL,Stoter G,Verweij J

更新日期：1998-10-01 00:00:00

abstract：:Taxanes have had a profound impact on the management of genitourinary tumors. In the perioperative and metastatic setting in bladder cancer, taxanes such as paclitaxel have an established role in combination chemotherapy strategies to improve survival. In metastatic prostate cancer, docetaxel was the only treatment, u...

journal_title：Anti-cancer drugs

authors： Balar AV

更新日期：2014-05-01 00:00:00

abstract：:Urothelial carcinoma of the bladder accounts for over 95% of bladder tumours in France. The incidence of this disease is increasing in industrialised countries. Several types of bladder cancer can be distinguished: (1) superficial tumours which have a risk of recurrence and progression, although conservative treatment...

journal_title：Anti-cancer drugs

authors： Rischmann P

更新日期：2000-10-01 00:00:00

abstract：:This study aims to explore the effect and mechanism of pyruvate kinase M2 (PKM2) on chemotherapy resistance of estrogen receptor-positive breast cancer (ER BC) by regulating aerobic glycolysis. The expression of PKM2 in ER BC MCF-7 cells, T47D cells and MCF-7/ADR cells (which are subject to adriamycin/ADR induction) w...

journal_title：Anti-cancer drugs

authors： Qian Y,Bi L,Yang Y,Wang D

更新日期：2018-08-01 00:00:00

abstract：:Transcatheter arterial chemoembolization (TACE) is widely used to treat unresectable hepatocellular carcinoma (HCC). Recently, a fine-powder formulation of cisplatin (DDP-H) was developed in Japan. We aimed to compare clinical outcomes after TACE using epirubicin or DDP-H in patients with HCC. We evaluated 202 patient...

journal_title：Anti-cancer drugs

authors： Yodono H,Matsuo K,Shinohara A

更新日期：2011-03-01 00:00:00

abstract：:Pancreatic neuroendocrine tumors (PNETs) are rare malignancies that arise from the islets of Langerhans. The role of standard chemotherapy in advanced well-differentiated PNETs remains to be defined. Sunitinib is an oral multitargeted inhibitor with antiangiogenic and antitumor properties that has shown significant im...

journal_title：Anti-cancer drugs

authors： Grande E,José Díez J,Pachón V,Angeles Vaz M,Longo F,Guillén C,García de Paredes ML,Carrato A

更新日期：2011-06-01 00:00:00

abstract：:It is well known that the anti-cancer drug cisplatin has an ototoxic property; however, the details are not yet evident. In this study, the expression of inducible nitric oxide synthase (INOS/NOS II) in the vestibule of guinea pigs after i.p. injections of cisplatin was examined immunohistochemically. Three days after...

journal_title：Anti-cancer drugs

authors： Watanabe K,Hess A,Bloch W,Michel O

更新日期：2000-01-01 00:00:00

abstract：:Ecteinascidin 743 (Et743) is an interesting compound in phase II/III clinical trials. Its chemistry is complex, its mechanism of action is original and it is active in human cancers, such as sarcomas refractory to conventional chemotherapy. The present review describes the discovery of the drug, its specific interacti...

journal_title：Anti-cancer drugs

authors： Aune GJ,Furuta T,Pommier Y

更新日期：2002-07-01 00:00:00

abstract：:Hormonal agents have a confirmed role in the management of postmenopausal women with receptor-positive advanced breast cancer. Until recently, tamoxifen has been the accepted agent for treating these patients. However, accumulating evidence suggests that the new antiaromatase agents will replace the antiestrogens as t...

journal_title：Anti-cancer drugs

authors： Vogel CL

更新日期：2003-04-01 00:00:00

abstract：:Targeted agents such as sunitinib, an oral, multitargeted receptor tyrosine kinase inhibitor, have greatly improved the prognosis for patients with metastatic renal cell carcinoma (mRCC). In this review we analyse data from sunitinib preclinical and clinical studies in detail and consider the key implications for the ...

journal_title：Anti-cancer drugs

authors： Ravaud A,Bello CL

更新日期：2011-06-01 00:00:00

abstract：:The clinical development of combinations of cisplatin or carboplatin with DNA topoisomerase I (Topo I) inhibitors is based on their overlapping spectrum of antitumor activity and their in vitro synergy, but is limited by significant hematotoxicity. We studied the cellular interactions between oxaliplatin and topotecan...

journal_title：Anti-cancer drugs

authors： Goldwasser F,Bozec L,Zeghari-Squalli N,Misset JL

更新日期：1999-02-01 00:00:00

abstract：:α-Lipoic acid (α-LA) is a biogenic antioxidant that has been used successfully in the treatment of diabetic polyneuropathy and its application to many oxidative stress-associated chronic diseases has increased. In this study, we investigated the effect of α-LA on colorectal cancer cell growth and its underlying mechan...

journal_title：Anti-cancer drugs

authors： Yoo TH,Lee JH,Chun HS,Chi SG

更新日期：2013-07-01 00:00:00

abstract：:Renal cell carcinoma (RCC) is one of the most frequent malignancies of the adults. Its incidence has been increasing steadily by 2-4% each year. Up to 30% of patients present with metastases at diagnosis. It is a highly vascularized cancer because of the hypoxia-induced factor stabilization as a consequence of von Hip...

journal_title：Anti-cancer drugs

authors： Nigro O,Pastore A,Tartaro T,Bolzacchini E,Tuzi A,Pinotti G

更新日期：2019-04-01 00:00:00

abstract：UNLABELLED:Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performa...

journal_title：Anti-cancer drugs

authors： Kudelka AP,Winn R,Edwards CL,Downey G,Greenberg H,Dakhil SR,Freedman RS,LoCoco S,Umbreit J,Delmore JE,Arbuck S,Loyer E,Gacrama P,Fueger R,Kavanagh JJ

更新日期：1997-08-01 00:00:00

abstract：:The aim of this study was to evaluate the efficacy and tolerability of the combination of paclitaxel and nedaplatin in patients with advanced esophageal cancer. Patients (n = 310) with recurrent or metastatic esophageal squamous cell carcinoma, who had a maximum of one previous chemotherapy regimen, were enrolled in t...

journal_title：Anti-cancer drugs

authors： Du J,Hu C,Zhang Y,Hu B,Wang F,Zhang Y

更新日期：2015-01-01 00:00:00

abstract：:Substitutions in thiophene structure give rise to new derivatives with different biological and pharmacological activities. The present study investigated the cytotoxicity activity of some thiophene derivatives in breast cancer cells maintained in two-dimensional (2D) or in three-dimensional (3D) culture and evaluated...

journal_title：Anti-cancer drugs

authors： Dos Santos FA,Pereira MC,de Oliveira TB,Mendonça Junior FJB,de Lima MDCA,Pitta MGDR,Pitta IDR,de Melo Rêgo MJB,da Rocha Pitta MG

更新日期：2018-02-01 00:00:00

abstract：:A drug-resistant cell line (EAC/Dox) was developed by repeated exposure of Ehrlich ascites carcinoma cells to Doxorubicin (Dox) in vivo in male albino Swiss mice (6-8 weeks old). The weekly i.p. injections of Dox to mice (2 or 4 mg/kg/week for 4 months) gave rise to Dox-resistant cell line EAC/Dox, which displayed typ...

journal_title：Anti-cancer drugs

authors： Choudhuri SK,Chatterjee A

更新日期：1998-10-01 00:00:00

abstract：:We examined the anti-tumor activity and structure-activity requirements of omega-hydroxy fatty acids (omega-HFAs) on the human melanoma cell line G361. The omega-hydroxystearic acid (omega-HSA) had strong growth-inhibiting and cytotoxic activity. Although omega-hydroxypalmitic acid (omega-HPA) also had growth-inhibiti...

journal_title：Anti-cancer drugs

authors： Abe A,Sugiyama K

更新日期：2005-06-01 00:00:00

abstract：:Targeting of cytotoxic agents represents a modern approach to the treatment of various cancers, that improves the efficacy and reduces peripheral toxicity. Recently we developed a powerful cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AN-207, designed to be targeted to tumors that express LHRH rece...

journal_title：Anti-cancer drugs

authors： Arencibia JM,Schally AV,Halmos G,Nagy A,Kiaris H

更新日期：2001-01-01 00:00:00

abstract：:Thioredoxin (Trx) expression is increased in several human primary cancers associated with aggressive tumor growth and decreased patient survival, and the Trx/Trx reductase (TrxR) system therefore provides an attractive target for cancer drug development. Various gold(III) compounds with none, one, two or three carbon...

journal_title：Anti-cancer drugs

authors： Engman L,McNaughton M,Gajewska M,Kumar S,Birmingham A,Powis G

更新日期：2006-06-01 00:00:00

abstract：:Since their addition to paclitaxel in the oncologists' armamentarium in the early 1990s, several new taxane formulations have been developed. Besides docetaxel and nab-paclitaxel, new analogs with better therapeutic profiles are being investigated. The goals of this next generation of taxanes are to improve the toxici...

journal_title：Anti-cancer drugs

authors： Muggia F,Kudlowitz D

更新日期：2014-05-01 00:00:00

abstract：:This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination. Patients with non-small cell lung cancer were eligible. Treatment consisted of Ro 40-8757 p.o. day 1-21,...

journal_title：Anti-cancer drugs

authors： van Zuylen L,Schellens JH,Goey SH,Pronk LC,de Boer-Dennert MM,Loos WJ,Ma J,Stoter G,Verweij J

更新日期：1999-04-01 00:00:00

abstract：:Since 5-fluorouracil (5-FU) was synthesized in the late 1950s it has become an important component of many anticancer treatment regimens. The increasing volume of literature accumulating about this drug is evidence that the optimal administration schedule and its combination with modulators has yet to be determined. M...

journal_title：Anti-cancer drugs

authors： Findlay MP,Leach MO

更新日期：1994-06-01 00:00:00